Literature DB >> 25451132

Neurotrophic factors for spinal cord repair: Which, where, how and when to apply, and for what period of time?

Alan R Harvey1, Sarah J Lovett2, Bernadette T Majda2, Jun H Yoon2, Lachlan P G Wheeler2, Stuart I Hodgetts2.   

Abstract

A variety of neurotrophic factors have been used in attempts to improve morphological and behavioural outcomes after experimental spinal cord injury (SCI). Here we review many of these factors, their cellular targets, and their therapeutic impact on spinal cord repair in different, primarily rodent, models of SCI. A majority of studies report favourable outcomes but results are by no means consistent, thus a major aim of this review is to consider how best to apply neurotrophic factors after SCI to optimize their therapeutic potential. In addition to which factors are chosen, many variables need be considered when delivering trophic support, including where and when to apply a given factor or factors, how such factors are administered, at what dose, and for how long. Overall, the majority of studies have applied neurotrophic support in or close to the spinal cord lesion site, in the acute or sub-acute phase (0-14 days post-injury). Far fewer chronic SCI studies have been undertaken. In addition, comparatively fewer studies have administered neurotrophic factors directly to the cell bodies of injured neurons; yet in other instructive rodent models of CNS injury, for example optic nerve crush or transection, therapies are targeted directly at the injured neurons themselves, the retinal ganglion cells. The mode of delivery of neurotrophic factors is also an important variable, whether delivered by acute injection of recombinant proteins, sub-acute or chronic delivery using osmotic minipumps, cell-mediated delivery, delivery using polymer release vehicles or supporting bridges of some sort, or the use of gene therapy to modify neurons, glial cells or precursor/stem cells. Neurotrophic factors are often used in combination with cell or tissue grafts and/or other pharmacotherapeutic agents. Finally, the dose and time-course of delivery of trophic support should ideally be tailored to suit specific biological requirements, whether they relate to neuronal survival, axonal sparing/sprouting, or the long-distance regeneration of axons ending in a different mode of growth associated with terminal arborization and renewed synaptogenesis. This article is part of a Special Issue entitled SI: Spinal cord injury.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Cell death; Ciliary neurotrophic factor; Fibroblast growth factor; Glial cell-derived neurotrophic factor; Nerve growth factor; Neurotrophic factors; Neurotrophin-3; Plasticity; Platelet-derived neurotrophic factor; Regeneration; Spinal cord injury

Mesh:

Substances:

Year:  2014        PMID: 25451132     DOI: 10.1016/j.brainres.2014.10.049

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  34 in total

Review 1.  Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it?

Authors:  John Bianco; Pauline De Berdt; Ronald Deumens; Anne des Rieux
Journal:  Cell Mol Life Sci       Date:  2016-01-14       Impact factor: 9.261

2.  Astrocytes Protect against Isoflurane Neurotoxicity by Buffering pro-brain-derived Neurotrophic Factor.

Authors:  Creed M Stary; Xiaoyun Sun; Rona G Giffard
Journal:  Anesthesiology       Date:  2015-10       Impact factor: 7.892

3.  Aligned fibrous PVDF-TrFE scaffolds with Schwann cells support neurite extension and myelination in vitro.

Authors:  Siliang Wu; Ming-Shuo Chen; Patrice Maurel; Yee-Shuan Lee; Mary Bartlett Bunge; Treena Livingston Arinzeh
Journal:  J Neural Eng       Date:  2018-05-24       Impact factor: 5.379

Review 4.  Recent advances in nanotherapeutic strategies for spinal cord injury repair.

Authors:  Young Hye Song; Nikunj K Agrawal; Jonathan M Griffin; Christine E Schmidt
Journal:  Adv Drug Deliv Rev       Date:  2018-12-22       Impact factor: 15.470

Review 5.  Cell Therapeutic Strategies for Spinal Cord Injury.

Authors:  Pinghui Zhou; Jingjing Guan; Panpan Xu; Jingwen Zhao; Changchun Zhang; Bin Zhang; Yingji Mao; Wenguo Cui
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-10-16       Impact factor: 4.730

6.  Blocking of BDNF-TrkB signaling inhibits the promotion effect of neurological function recovery after treadmill training in rats with spinal cord injury.

Authors:  Xiangzhe Li; Qinfeng Wu; Caizhong Xie; Can Wang; Qinghua Wang; Chuanming Dong; Lu Fang; Jie Ding; Tong Wang
Journal:  Spinal Cord       Date:  2018-07-12       Impact factor: 2.772

Review 7.  Functional recovery after cervical spinal cord injury: Role of neurotrophin and glutamatergic signaling in phrenic motoneurons.

Authors:  Luther C Gill; Heather M Gransee; Gary C Sieck; Carlos B Mantilla
Journal:  Respir Physiol Neurobiol       Date:  2015-10-23       Impact factor: 1.931

8.  Gene Transfer of Brain-derived Neurotrophic Factor (BDNF) Prevents Neurodegeneration Triggered by FXN Deficiency.

Authors:  Yurika Katsu-Jiménez; Frida Loría; Juan Carlos Corona; Javier Díaz-Nido
Journal:  Mol Ther       Date:  2016-02-05       Impact factor: 11.454

9.  Neurotrophin-3 provides neuroprotection via TrkC receptor dependent pErk5 activation in a rat surgical brain injury model.

Authors:  Onat Akyol; Prativa Sherchan; Gokce Yilmaz; Cesar Reis; Wingi Man Ho; Yuechun Wang; Lei Huang; Ihsan Solaroglu; John H Zhang
Journal:  Exp Neurol       Date:  2018-06-05       Impact factor: 5.330

10.  Cationic, amphiphilic copolymer micelles as nucleic acid carriers for enhanced transfection in rat spinal cord.

Authors:  So-Jung Gwak; Justin Nice; Jeremy Zhang; Benjamin Green; Christian Macks; Sooneon Bae; Ken Webb; Jeoung Soo Lee
Journal:  Acta Biomater       Date:  2016-02-09       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.